186 related articles for article (PubMed ID: 11228536)
1. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
3. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
4. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
Horiguchi Y; Larchian WA; Kaplinsky R; Fair WR; Heston WD
Gene Ther; 2000 May; 7(10):844-51. PubMed ID: 10845722
[TBL] [Abstract][Full Text] [Related]
5. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
Siemens DR; Crist S; Austin JC; Tartaglia J; Ratliff T
J Urol; 2003 Sep; 170(3):979-84. PubMed ID: 12913754
[TBL] [Abstract][Full Text] [Related]
6. Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors.
Zang Z; Mahendran R; Wu Q; Yong T; Esuvaranathan K
Int J Mol Med; 2004 Oct; 14(4):713-7. PubMed ID: 15375606
[TBL] [Abstract][Full Text] [Related]
7. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
8. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
9. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
[TBL] [Abstract][Full Text] [Related]
10. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
11. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer.
Yamashita M; Rosser CJ; Zhou JH; Zhang XQ; Connor RJ; Engler H; Maneval DC; Karashima T; Czerniak BA; Dinney CP; Benedict WF
Cancer Gene Ther; 2002 Aug; 9(8):687-91. PubMed ID: 12136430
[TBL] [Abstract][Full Text] [Related]
12. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
[TBL] [Abstract][Full Text] [Related]
13. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
Wang H; Satoh M; Abe H; Sunamura M; Moriya T; Ishidoya S; Saito S; Hamada H; Arai Y
Urology; 2006 Sep; 68(3):674-81. PubMed ID: 16979729
[TBL] [Abstract][Full Text] [Related]
16. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells.
Dumey N; Mongiat-Artus P; Devauchelle P; Lesourd A; Cotard JP; Le Duc A; Marty M; Cussenot O; Cohen-Haguenauer O
Eur Urol; 2005 Feb; 47(2):257-63. PubMed ID: 15661423
[TBL] [Abstract][Full Text] [Related]
17. A system for the enhancement of adenovirus mediated gene transfer to uro-epithelium.
Lin LF; Zhu G; Yoo JJ; Soker S; Sukhatme VP; Atala A
J Urol; 2002 Aug; 168(2):813-8. PubMed ID: 12131373
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice.
Yoon SK; Armentano D; Wands JR; Mohr L
Cancer Gene Ther; 2001 Aug; 8(8):573-9. PubMed ID: 11571535
[TBL] [Abstract][Full Text] [Related]
19. [Gelsolin gene therapy using adenovirus vector for orthotopically implanted human urinary bladder carcinoma in nude mice].
Sazawa A
Hokkaido Igaku Zasshi; 2001 Jul; 76(4):263-71. PubMed ID: 11523117
[No Abstract] [Full Text] [Related]
20. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.
Nogawa M; Yuasa T; Kimura S; Tanaka M; Kuroda J; Sato K; Yokota A; Segawa H; Toda Y; Kageyama S; Yoshiki T; Okada Y; Maekawa T
J Clin Invest; 2005 Apr; 115(4):978-85. PubMed ID: 15761500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
